Tempus AI 배당 및 자사주 매입
배당 기준 점검 0/6
Tempus AI 배당금을 지급한 기록이 없습니다.
핵심 정보
n/a
배당 수익률
-1.9%
자사주 매입 수익률
| 총 주주 수익률 | -1.9% |
| 미래 배당 수익률 | 0% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | n/a |
최근 배당 및 자사주 매입 업데이트
업데이트 없음
Recent updates
Seeking Alpha • Jun 30
Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
Summary Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expanding FDA-approved offerings. Recent FDA approval for xT CDx's tumor-only indication and the upcoming xH assay broaden TEM's clinical reach and addressable markets. AI-powered Lens and Next platforms drive adoption among top biopharma and improve clinical outcomes, reinforcing TEM's data flywheel and competitive moat. Despite high EV/Sales multiples and cash burn, robust revenue growth and margin improvement support the premium AI/tech valuation thesis. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 27
TEM: FDA Approvals And Data Platform Progress Will Drive Future Upside
The analyst fair value estimate for Tempus AI has shifted from about $105.00 to roughly $95.45, as analysts recalibrate assumptions on revenue growth, profit margins, discount rate, and future P/E in light of recent mixed research that praises the company's differentiated data platform while questioning the clarity and timing of long term monetization. Analyst Commentary Recent Street research on Tempus AI points to a mixed but active debate, with several bullish analysts highlighting strengths in the company’s data platform and potential for execution on its long term roadmap.분석 기사 • Jun 19
Tempus AI (TEM) Stock Could Be 22.9% Undervalued After ECG AF Validation
Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF. See our latest analysis for Tempus AI. Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%...
내러티브 업데이트 • Jun 13
TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand
Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.
새로운 내러티브 • Jun 09
An Overlooked AI Play That’s Quietly Building a Healthcare Data Empire
Tempus AI isn't simply an AI software business (not another ChatBot). It's building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.내러티브 업데이트 • May 30
TEM: FDA Approvals And Partnerships Will Support Future Oncology Data Demand
Narrative Update The average analyst price target for Tempus AI has moved lower by several dollars to reflect a mix of reduced targets from H.C. Wainwright, BTIG, Baird, Guggenheim, and Morgan Stanley, partially offset by modest upward revisions and an upgrade from TD Cowen and TD Securities. Analysts are incorporating recent results, updated models, and ongoing partnership activity into their assessments.내러티브 업데이트 • May 13
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Upside
Tempus AI's analyst price target is now $67.20, down from $72.40, as analysts adjust their models to reflect more moderate revenue growth assumptions and mixed recent price target revisions across the Street. Analyst Commentary Recent research on Tempus AI shows a mix of optimism and caution as analysts update their models, adjust price targets, and refine views following Q4 results and new coverage initiations.내러티브 업데이트 • Apr 28
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Monetization
Analysts have slightly reduced the blended price target on Tempus AI to $72.40. This reflects updated models around revenue growth, profit margins and P/E assumptions after a mix of target cuts and increases across recent research, including responses to Q4 results and ongoing partnership momentum.내러티브 업데이트 • Apr 13
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Leadership
Narrative Update on Tempus AI The updated analyst price target for Tempus AI moves to $72.73 from $77.93, as analysts factor in slightly higher discount rates and a lower future P/E multiple. They still point to ongoing partnerships and data backlog as key supports for the long term story.내러티브 업데이트 • Mar 26
TEM: Data Partnerships And Backlog Will Drive Future Precision Oncology Execution
Analysts report a modestly adjusted fair value estimate of $77.93 per share for Tempus AI, reflecting mixed price target revisions that weigh the impact of new partnerships and data backlog strength against updated post Q4 models and views on visibility in parts of the business. Analyst Commentary Recent Street research on Tempus AI reflects a split view, with some focusing on growth potential in precision medicine and data, and others emphasizing execution risks and visibility in parts of the business.내러티브 업데이트 • Mar 11
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Upside
Our updated view trims Tempus AI's implied fair value from about $86.71 to $77.93 per share, reflecting analysts' mixed price target revisions after Q4. Some highlight expanding pharma and academic partnerships and a large data backlog, while others factor in model updates, valuation resets, and questions around data upside and Ambry.
새로운 내러티브 • Mar 04
Heavy AI Infrastructure And Rising Costs Will Pressure Data Economics Yet Eventually Support Upside
Catalysts About Tempus AI Tempus AI provides AI driven molecular diagnostics and data products to support clinical decision making and drug development. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 24
TEM: Precision Oncology And AI Biomarkers Will Support Future Upside Potential
Narrative update on Tempus AI The updated analyst price target for Tempus AI has edged down by about $1 to reflect slightly lower fair value and profit margin assumptions, even as analysts highlight the company's role in precision oncology diagnostics and AI-enabled healthcare data services as a key factor in its long term revenue growth outlook. Analyst Commentary Recent research coverage on Tempus AI highlights both enthusiasm for its role in precision oncology and AI driven healthcare data, and a set of execution and valuation questions that investors are watching closely.새로운 내러티브 • Feb 18
Genomics And AI Data Licensing Will Transform Long Term Oncology Outcomes
Catalysts About Tempus AI Tempus AI operates a genomics and data platform focused on Oncology and related clinical insights. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 10
TEM: AI Biomarker Advancements In Oncology Will Drive Future Returns
Analysts have nudged their price target on Tempus AI higher to about US$87.92, citing slightly stronger modeled revenue growth, profit margins, and a marginally lower future P/E assumption in their updated forecasts. What's in the News Tempus reported new clinical validation data for its Immune Profile Score test, indicating that the algorithmic biomarker more accurately predicts outcomes for patients receiving immune checkpoint inhibitors than several conventional biomarkers across multiple metastatic solid tumor cohorts.내러티브 업데이트 • Jan 26
TEM: Oncology Data Collaborations And AI Pathology Will Drive Future Returns
Analysts have kept their fair value estimate for Tempus AI steady at about US$87.92 per share, with only very small tweaks to inputs like discount rate, revenue growth, profit margins and future P/E assumptions supporting an unchanged overall target. What's in the News Tempus AI launched Paige Predict, a suite of AI pathology tools that analyze H&E whole slide images to help predict the likelihood of 123 biomarkers and oncogenic pathways across 16 cancer types, with results delivered alongside clinical reports to physicians (Product-Related Announcements).내러티브 업데이트 • Jan 12
TEM: Oncology Data Collaborations Will Drive Future Returns Despite Slightly Higher Risk
Analysts have trimmed their fair value estimate for Tempus AI by about US$1.00, reflecting slightly higher discount rate assumptions as well as marginally adjusted revenue growth, profit margin, and future P/E inputs. What's in the News Tempus AI plans to present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, focusing on multimodal real world data, risk stratification for CDK4/6 inhibitor plus endocrine therapy, and tumor microenvironment signatures in hormone receptor positive, HER2 negative metastatic breast cancer (Key Developments).내러티브 업데이트 • Dec 25
TEM: Future Oncology Data Partnerships Will Drive Profits Despite Modestly Higher Risk
Analysts have modestly reduced their price target on Tempus AI by approximately 3 dollars, reflecting slightly higher perceived risk and marginally slower long term growth expectations, partly offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Tempus AI will present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, showcasing multimodal real world data approaches to better stratify metastatic breast cancer patients and identify responders to CDK4/6 inhibitors (Key Developments).내러티브 업데이트 • Dec 11
TEM: Future Profit Margins Will Expand As Federal Oncology Program Catalysts Mature
Narrative Update on Tempus AI Analyst Price Target Analysts have slightly raised their price target on Tempus AI to approximately 91 dollars and 42 cents from 91 dollars, citing a marginally lower perceived risk profile and stable long term growth and profitability assumptions. What's in the News Tempus received FDA 510(k) clearance for its RNA based xR IVD sequencing assay, expanding its toolkit for drug development partners and strengthening its position as a comprehensive precision oncology platform (FDA filing).내러티브 업데이트 • Nov 26
TEM: Future Profit Margins Will Expand With AI-Powered Clinical Partnerships
Analysts have revised Tempus AI's price target upwards from $87.17 to $91.00, citing improved profit margin projections and a significantly lower anticipated future price-to-earnings ratio. What's in the News Tempus AI and the Institute for Follicular Lymphoma Innovation (IFLI) launched their first collaborative research study with a non-profit foundation to create a comprehensive, multi-omic dataset for follicular lymphoma.내러티브 업데이트 • Nov 09
TEM: Revenue Will Accelerate With New Real-World Data Partnership
Analysts have raised their price target for Tempus AI from $82.50 to $87.17, citing shifts in expected growth and profitability as supporting factors for the updated valuation. What's in the News Tempus AI announced six new abstracts accepted for presentation at the SITC Annual Meeting 2025, highlighting advances in multi-omic algorithms and biomarkers for rare and advanced cancers (Product-Related Announcements).내러티브 업데이트 • Oct 26
Advances In Precision Medicine And AI Will Reshape Cancer Care Futures
Analysts have raised their price target for Tempus AI from $77.55 to $82.50, citing stronger confidence in revenue growth and profitability projections. What's in the News Tempus AI and Whitehawk Therapeutics announced a multi-year collaboration to use Tempus' real-world dataset to advance biomarker-driven research and enhance oncology clinical trial design.내러티브 업데이트 • Oct 12
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI's fair value estimate has been raised by analysts from $74.82 to $77.55 per share. This reflects optimism about improved revenue growth and updated market outlooks.분석 기사 • Oct 09
After Leaping 29% Tempus AI, Inc. (NASDAQ:TEM) Shares Are Not Flying Under The Radar
Despite an already strong run, Tempus AI, Inc. ( NASDAQ:TEM ) shares have been powering on, with a gain of 29% in the...내러티브 업데이트 • Sep 28
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI’s valuation has become more expensive with a higher forward P/E and declining net profit margin, leading to only a marginal increase in the consensus analyst price target to $74.82. What's in the News Tempus AI received FDA 510(k) clearance for its RNA-based Tempus xR IVD device and updated Tempus Pixel cardiac imaging platform, expanding its diagnostics and AI imaging capabilities.내러티브 업데이트 • Sep 13
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI’s consensus future P/E and discount rate held steady with minimal movement, supporting only a slight upward revision in fair value from $72.73 to $73.45. What's in the News Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform, which now enables generation of T1 and T2 inline maps for enhanced cardiac MR image analysis, supporting more precise and efficient diagnostics.내러티브 업데이트 • Aug 27
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Tempus AI's slightly higher consensus price target reflects a significant increase in its future P/E ratio despite a decline in net profit margin, resulting in a new fair value estimate of $71. What's in the News Tempus AI filed a $500 million follow-on equity offering of Class A Common Stock via an at-the-market transaction and raised its full-year 2025 revenue guidance to approximately $1.26 billion, representing ~82% annual growth.분석 기사 • Aug 15
Tempus AI, Inc. (NASDAQ:TEM) Looks Just Right With A 28% Price Jump
Tempus AI, Inc. ( NASDAQ:TEM ) shareholders would be excited to see that the share price has had a great month, posting...새로운 내러티브 • Jun 15
AstraZeneca And Pathos Partnership Will Expand Precision Medicine
Pharma partnerships and the shift toward AI-driven precision medicine are fueling strong, high-margin revenue growth and expanding Tempus' competitive opportunities.지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 TEM 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: TEM 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| Tempus AI 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (TEM) | n/a |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.2% |
| 업계 평균 (Life Sciences) | 0.7% |
| 분석가 예측 (TEM) (최대 3년) | 0% |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 TEM 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 TEM 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 TEM 의 지급 비율을 계산하기에는 데이터가 부족합니다.
주주 현금 배당
현금 흐름 범위: TEM 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/30 21:09 |
| 종가 | 2026/06/30 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Tempus AI, Inc.는 22명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |